Visterra Shares Flu Data

mia.burns

Announces an Oral Presentation of VIS410 that Showed Neutralization of H5 and H7 Influenza Strains with Pandemic Potential

  • Preclinical results presented at ICAAC 2013 demonstrated the ability of VIS410 to neutralize influenza strains with pandemic potential, H5N1 and H7N9
  • VIS410, a novel engineered human antibody against seasonal and pandemic flu, is advancing to the clinic in 2014

Cambridge, MA – September 12, 2013 – Visterra, Inc., developer of novel therapeutics to treat major infectious diseases, announced positive preclinical data showing that VIS410 demonstrated neutralization of H5N1 and H7N9 influenza strains that have pandemic potential.  Developed using Visterra’s innovative antibody design technology, VIS410 is designed to be a broadly protective, fully human monoclonal antibody that targets a site on influenza hemagglutinin (HA) that is present across all influenza A subtypes and is resistant to mutation.  These data were presented in a late-breaking oral session today at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver.

“We are very encouraged by this data which showed the broad potential of VIS410 to neutralize two of the most dangerous influenza strains with pandemic potential, H5N1 and H7N9. If H5N1 or H7N9 strains evolve to transmit efficiently in humans, effective vaccines may be lacking or delayed for use in a pandemic setting, and VIS410 could be a critical new treatment option,” said Donna M. Ambrosino, M.D., Chief Medical Officer at Visterra. “With these results, VIS410 continues to demonstrate expanded potential across a broad spectrum of influenza A strains, bolstering our plans to develop VIS410 as a novel universal agent to prevent and treat both seasonal and pandemic influenza.”

Highlights of the oral presentation, titled “VIS410, a broadly HA-targeting human antibody, neutralizes H5 and H7 isolates with pandemic potential,”…Read more

Pharmalive – The Pulse of the Pharmaceutical Industry

Share This Post

Related Articles

Leave a Reply

© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS